Background: Primary myelofibrosis is a chronic myeloproliferative neoplasm that may cause
debilitating symptoms, which can be improved with the use of Ruxolitinib, a Janus kinase 2 …

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the
2016 revision of World Health Organization Classification of Tumors and Haematopoietic …

Ruxolitinib improves disease-related constitutional symptoms, splenomegaly and overall
survival in myelofibrosis. However, studies suggest that the drug exerts immunosuppressive …

Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition
of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway …

Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and
polycythemia vera (PV). Recent data have suggested the possibility of increased infectious …

Ruxolitinib is a novel inhibitor of the Janus kinase (JAK) pathway that has become available
for the treatment of myelofibrosis. There are increasing reports of opportunistic infections …

Ruxolitinib exerts immunosuppressive activity that may increase the risk of infectious
complications. We performed a systematic review of the literature with the aim of estimating …

Infections represent one of the major concerns regarding the utilization of ruxolitinib (RUX)
in patients with myelofibrosis. With the aim to investigate epidemiology, outcome and risk …

A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea,
which was changed to ruxolitinib treatment because of worsening constitutional symptoms …

Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis with
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …